Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Type 1 Diabetes

Type 1 Diabetes

Part of Diabetes

Subtypes of Type 1 Diabetes

Type 1 diabetes mellitus 13 Wolfram Syndrome 1

61 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Type 1 Diabetes

203 trials tracked for Type 1 Diabetes: 39 in phase 3 or 4 and 14 with published results. The most-cited published study has 181 citations.

203Trials tracked
39Phase 3 & 4
0Recruiting
14With published results
Phase distribution
Phase 4 14 Phase 3 25 Phase 2 29 Phase 1 9 Other / NA 126
  1. Phase 3 Metformin Therapy for Overweight Adolescents With Type 1 Diabetes Completed · 181 cited
  2. Phase 3 EMERALD: Effects of Metformin on Cardiovascular Function in Adolescents With Type 1 Diabetes Completed · 143 cited
  3. Phase 3 Efficacy Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Patients Completed · 63 cited
  4. Phase 3 A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy Completed · 47 cited
  5. Phase 4 52 Week Trial of Liraglutide in Type 1 Diabetes Completed · 38 cited
  6. Phase 4 Intravenous Insulin vs Subcutaneous Insulin Infusion in Intrapartum Management of Type 1 Diabetes Mellitus Completed · 15 cited
Show 44 more trials
  1. Phase 3 Targeting Inflammation With Salsalate in Type 1 Diabetes Neuropathy Completed · 9 cited
  2. Phase 4 Immune Intervention With Rituximab to Preserve Beta Cell Function in Early Onset Type 1 Diabetes Completed · 7 cited
  3. Phase 4 Afrezza With Basal Combination (ABC): Afrezza® Combined With AID Pump or Insulin Degludec in Adults With Type 1 Diabetes Completed · 6 cited
  4. Phase 4 Human Versus Analogue Insulin for Youth With Type 1 Diabetes in Low-Resource Settings Completed · 5 cited
  5. Phase 3 Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 1 Diabetes Mellitus Patients (INSTRIDE 1) Completed · 4 cited
  6. Phase 3 A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 1 Diabetes Mellitus Completed · 2 cited
  7. Phase 4 A Study to Evaluate Pneumococcal Polysaccharide Vaccine Effectiveness in Children With Type 1 Diabetes Completed · 1 cited
  8. Phase 4 A Study of Rapid-Acting Mealtime Insulin in Children and Adolescents With Newly Diagnosed Type 1 Diabetes Mellitus Completed · 1 cited
  9. Phase 4 Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia Completed
  10. Phase 4 Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 Diabetes Completed
  11. Phase 4 New Onset Type 1 Diabetes: Role of Exenatide Completed
  12. Phase 4 Insulin Pump to Multiple Daily Injection Transition Clinical Trial Completed
  13. Phase 4 Effect of Metformin on Vascular and Mitochondrial Function in Type 1 Diabetes Completed
  14. Phase 4 Comparison of Glargine to Degludec Insulin Transition With or Without a Bridging Glargine Dose Completed
  15. Phase 4 Feasibility Study for Training Pump Naïve Subjects To Use The Paradigm® System And Evaluate Effectiveness Completed
  16. Phase 3 Equivalence of A Stable Liquid Glucagon Formulation With Freshly Reconstituted Lyophilized Glucagon Completed
  17. Phase 3 A Study of LY900014 and Insulin Lispro With an External Continuous Subcutaneous Insulin Infusion System in Adult Participants With Type 1 Diabetes Completed
  18. Phase 3 Liraglutide In Overweight Patients With Type 1 Diabetes Completed
  19. Phase 3 Effects of Acipimox on Insulin Action, Vascular Function, and Muscle Function in Type 1 Diabetes Completed
  20. Phase 3 Liraglutide in Type 1 Diabetes Completed
  21. Phase 3 Vitamin D and Residual Beta-Cell Function in Type 1 Diabetes Completed
  22. Phase 3 Liraglutide in Adolescents With Type 1 Diabetes Completed
  23. Phase 3 A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1D Completed
  24. Phase 3 Study Comparing Effectiveness of Intraperitoneal Insulin Administration to Subcutaneous Insulin Administration Completed
  25. Phase 3 Comparison of Lantus and Neutral Protamine Hagedorn (NPH) Insulin in the Dawn Phenomenon Completed
  26. Phase 3 Outpatient Study to Evaluate Safety and Effectiveness of the Low Glucose Suspend Feature Completed
  27. Phase 3 STEP: Social Support To Empower Parents Completed
  28. Phase 3 Safety of Inhaled Insulin With Type 1 and Type 2 Diabetes Completed
  29. Phase 3 Diabetic Retinopathy Candesartan Trials Completed
  30. Phase 3 New Strategies for Postprandial Glycemic Control Using Insulin Pump Therapy Completed
  31. Phase 3 DIabetic Retinopathy Candesartan Trials. Completed
  32. Phase 3 Liraglutide in the Treatment of Type 1 Diabetes Mellitus Completed
  33. Phase 3 Randomized Study of Real-Time Continuous Glucose Monitors (RT-CGM) in the Management of Type 1 Diabetes Completed
  34. Phase 2 Combination Therapy With Sitagliptin and Lansoprazole to Restore Pancreatic Beta Cell Function in Recent-Onset Type 1 Diabetes Completed
  35. Phase 2 CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1 Completed
  36. Phase 2 Transdermal Basal Insulin Patch Study in Type 1 Diabetes Completed
  37. Phase 2 Incretin Effect and Use After Clinical Islet Transplantation Completed
  38. Phase 2 Naltrexone and Hypoglycemia in Type 1 Diabetes Completed
  39. Phase 2 Liraglutide Versus Insulin Mono-therapy in the Closed Loop Setting Completed
  40. Phase 2 Immune Effects of Oral Insulin in Relatives at Risk for Type 1 Diabetes Mellitus (TN20) Completed
  41. Phase 2 DiaBetter Together for Young Adults With Type 1 Diabetes Completed
  42. Phase 2 Diabetes Prevention - Immune Tolerance Completed
  43. Phase 2 Tauroursodeoxycholic Acid (TUDCA) in New-Onset Type 1 Diabetes Completed
  44. Phase 2 A Euglycemic Insulin Clamp Study in Type 1 Diabetic Patients With Oral Insulin (ORAMED) Completed

Showing the 50 most-cited and recently-updated of 203 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Type 1 Diabetes: what the trials found

Clinical trials for Type 1 Diabetes have evaluated various pharmacological and delivery interventions. Insulin Glargine was assessed regarding Time-in-Range (TIR), time in hypoglycemia, and time in serious hypoglycemia; however, no statistically significant differences were observed between groups across these metrics 14.

Multiple daily injections using a combination of Insulin Degludec and Insulin Aspart showed varying results compared to the control group: the treatment group had higher time spent with glucose levels >180 mg/dL (46.3% vs 38.5%), lower time in hypoglycemia <70 mg/dl (3.9% vs 2.1%), and lower Time-in-Range (47.8% vs 56.5%) 19.

Rapid-acting insulin was evaluated for its impact on caregiver treatment adherence and glycemic variability, with results showing significant differences in these metrics at the 1-month and 4-month post-intervention marks 16.

Insulin Degludec did not show statistically significant changes in mean percent Time in Range, Coefficient of Variation of TIR, or Nocturnal Time in Range (70-180 mg/dL) 17.

Recent results — preliminary, needs further review

  • The AIDANET system showed significantly higher TIR during 18-hour hotel sessions compared to at-home settings (85.7% vs 71.7%, p=0.02) 1.
  • Tandem t:slim X2 with extended bolus demonstrated a TIR of approximately 71-73% and 0% time in hypoglycemia 2.
  • MPC closed-loop systems showed significantly lower incremental Area Under the Curve of postprandial glucose following the first meal (18.1 vs 20.9, p=0.017) 6.
  • Psychoeducation to reduce diabetes distress did not result in statistically significant improvements in TIR, A1c, or distress scores 3.

For the clinician treating this condition

  • Insulin Glargine and Insulin Degludec showed no statistically significant differences in primary glycemic metrics such as Time-in-Range or hypoglycemia duration compared to controls [14, 17].
  • Combination therapy of Insulin Degludec and Insulin Aspart resulted in higher instances of hyperglycemia (>180 mg/dL) but lower rates of hypoglycemia (<70 mg/dl) compared to the control group 19.
  • Advanced delivery systems like AIDANET showed significantly improved Time-in-Range during specific high-variability scenarios (e.g., hotel sessions) compared to at-home settings 1.

AI synthesis of 8 cited trials, updated Jun 20, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Meta-analysis finds 8.33% pooled prevalence of new-onset diabetes after SARS-CoV-2 infection in adults
Diabetes & Endocrinology Meta-analysis
Meta-analysis finds 8.33% pooled prevalence of new-onset diabetes after SARS-CoV-2 infection in adults Study finds link between COVID-19 infection and new diabetes diagnoses in adults
A systematic review and meta-analysis of 33 observational studies in adults following SARS-CoV-2 infection found a pooled prevalence of new-…
About 8.3% of adults develop new diabetes after COVID-19 infection, with type 2 cases making up most of the diagnoses in a review of 33 stud…
Apr 2, 2026

Research across Diabetes

Related studies from across the Diabetes family.

Fragmented patient-reported outcome measures currently characterize the clinical landscape of type 3c diabetes
Diabetes & Endocrinology Sys. Review
Fragmented patient-reported outcome measures currently characterize the clinical landscape of type 3c diabetes Mapping how patients experience life with type 3c diabetes
This scoping review of 40 reports maps standardized patient-reported outcome measures (PROMs) in adults with type 3c diabetes. Findings indi…
Living with type 3c diabetes after a total pancreatectomy often impacts physical function and general health, but more consistent tracking i…
Frontiers Sep 14, 2026
Antidiabetic drugs and gut microbiota interact to influence treatment efficacy and tolerability in metabolic syndrome
Diabetes & Endocrinology Sys. Review
Antidiabetic drugs and gut microbiota interact to influence treatment efficacy and tolerability in metabolic syndrome Gut bacteria may influence how well diabetes drugs work
This narrative review explores how gut microbiota dysbiosis contributes to metabolic syndrome and type 2 diabetes. It synthesizes evidence t…
Your gut bacteria might be the secret reason why some people respond better to diabetes medications than others.
Frontiers Sep 13, 2026
Metabolomics profiling identifies amino acid and lipid metabolism alterations in patients with diabetes mellitus
Nutrition & Obesity Medicine Meta-analysis
Metabolomics profiling identifies amino acid and lipid metabolism alterations in patients with diabetes mellitus Metabolomics Profiling Identifies Key Markers for Diabetes Management
This systematic review of 188 studies examines metabolomics profiling to identify metabolite signatures associated with diabetes and glucose…
New research highlights how metabolomics can identify specific patterns in amino acids and lipids to help manage and predict diabetes outcom…
Frontiers Sep 12, 2026
Ecnoglutide improves glycemic control and reduces body weight in adults with type 2 diabetes
Diabetes & Endocrinology Meta-analysis
Ecnoglutide improves glycemic control and reduces body weight in adults with type 2 diabetes Ecnoglutide Shows Promise for Type 2 Diabetes Management
This meta-analysis evaluated the efficacy of ecnoglutide in adults with type 2 diabetes compared to placebo and dulaglutide. The findings in…
Ecnoglutide may help manage blood sugar and reduce body weight in adults with type 2 diabetes, though more large-scale studies are needed.
Frontiers Sep 11, 2026
Short-bout accumulated physical activity reduces mean glucose in adults with type 2 diabetes
Diabetes & Endocrinology Meta-analysis
Short-bout accumulated physical activity reduces mean glucose in adults with type 2 diabetes Short bursts of activity may lower blood sugar in diabetes
This meta-analysis of 175 participants indicates that short-bout accumulated physical activity and sedentary-break interventions reduce mean…
Short bursts of physical activity and frequent breaks from sitting may help lower average blood sugar levels for adults with type 2 diabetes…
Frontiers Sep 11, 2026
CABG reduces all-cause death and repeat revascularisation risk in patients with diabetes and CKD
Cardiology RCT
CABG reduces all-cause death and repeat revascularisation risk in patients with diabetes and CKD CABG Shows Lower Risk for Patients with Diabetes and CKD
This systematic review and meta-analysis of 10594 patients with multivessel coronary disease and multiple long-term conditions found CABG fa…
Surgery may offer better outcomes than other procedures for patients with heart disease who also have diabetes and chronic kidney disease.
medRxiv Sep 9, 2026
OSA Tied to Poorer Glucose Control in Type 2 Diabetes
Diabetes & Endocrinology Meta-analysis
OSA Tied to Poorer Glucose Control in Type 2 Diabetes Sleep Apnea Linked to Poorer Blood Sugar Control in Diabetes
Obstructive sleep apnoea is consistently linked to worse glucose control and insulin resistance in people with type 2 diabetes or prediabete…
People with Type 2 Diabetes and sleep apnea may face harder blood sugar management and higher insulin resistance.
Frontiers Sep 9, 2026
Survodutide Improves Beta Cell Function and Insulin Sensitivity in T2D and Obesity
Nutrition & Obesity Medicine RCT
Survodutide Improves Beta Cell Function and Insulin Sensitivity in T2D and Obesity Trial shows survodutide improves insulin sensitivity and beta-cell function
Survodutide demonstrates significant improvements in beta-cell function and insulin sensitivity across both T2D and overweight populations.
A new medication called survodutide may improve how the body handles insulin and supports the cells that produce it for people with type 2 d…
Sep 8, 2026
Comparative Efficacy of GLP-1 Receptor Agonists for Adolescent Obesity and Type 2 Diabetes
Nutrition & Obesity Medicine Sys. Review
Comparative Efficacy of GLP-1 Receptor Agonists for Adolescent Obesity and Type 2 Diabetes Trial shows different GLP-1 medications impact weight and blood sugar
A network meta-analysis evaluates GLP-1 receptor agonists in adolescents, identifying varying degrees of efficacy across weight, glucose, an…
New analysis of GLP-1 medications shows varying results for weight loss and blood sugar control in adolescents with obesity and type 2 diabe…
Sep 7, 2026
Only 10% of Chinese adults with diabetes demonstrate good practices for diabetic foot care
Primary Care & Family Medicine Meta-analysis
Only 10% of Chinese adults with diabetes demonstrate good practices for diabetic foot care Most people with diabetes lack good foot care practices
This systematic review and meta-analysis of 6,124 Chinese adults with diabetes identifies significant gaps in foot care knowledge and practi…
A large study of over 6,000 people shows that while many have positive attitudes toward foot care, very few actually perform good daily prac…
Frontiers Sep 7, 2026
SGLT2 inhibitors not tied to gastrointestinal cancer risk in type 2 diabetes meta-analysis
Oncology Meta-analysis
SGLT2 inhibitors not tied to gastrointestinal cancer risk in type 2 diabetes meta-analysis SGLT2 inhibitors show no link to gastrointestinal cancer risk
This meta-analysis of 48,765 patients with type 2 diabetes found no significant association between SGLT2 inhibitor use and overall or site-…
New data suggests that SGLT2 inhibitors, a common treatment for type 2 diabetes, do not increase the risk of various gastrointestinal cancer…
Sep 6, 2026
CareAide mHealth application improves medication adherence and quality of life in type 2 diabetes
Diabetes & Endocrinology RCT
CareAide mHealth application improves medication adherence and quality of life in type 2 diabetes Pharmacist-led mobile app improves medication habits for type 2 diabetes
This multicentre randomized controlled trial of 663 patients with type 2 diabetes found that the CareAide mHealth application significantly …
A new mobile app led by pharmacists helps people with type 2 diabetes stay on track with their medications and improve their quality of life…
Sep 6, 2026

Questions about Type 1 Diabetes

Does the FDA approved drug Tzield delay the onset of Stage 3 Type 1 diabetes?

Yes, the FDA-approved drug Tzield (teplizumab) delays the onset of Stage 3 type 1 diabetes in people with Stage 2 disease.

Full answer →
Can semaglutide help reduce the total daily insulin dose for adults with Type 1 diabetes?

Yes, semaglutide can reduce total daily insulin dose in adults with type 1 diabetes and overweight or obesity, based on clinical trial and real-world data.

Full answer →